Emerging Biopharmaceuticals: The Future of Gene Therapy and Monoclonal Antibodies in Treating Chronic Diseases

Monoclonal antibodies (mAbs) and gene therapy are bringing major changes to how chronic diseases are treated. mAbs allow precise targeting in conditions like cancer, autoimmune disorders, and infections, though challenges like high costs and delivery limits remain. Innovations such as bispecific antibodies, nanobodies, and biosimilars are helping to improve results and lower costs. Gene therapy holds promise for genetic disorders, cancers, and chronic diseases, though regulatory and ethical issues slow its progress. New tools like CRISPR gene editing, non-viral delivery systems, and AI are pushing development forward. Gene editing works by changing, removing, or adding DNA sequences to correct defects or enhance traits. Ovarian and cervical cancers are the most common gynecologic cancers, with cervical cancer still causing high death rates. CRISPR-Cas9 offers hope in treating these cancers by targeting cancer-related genes and limiting tumor growth.